InBios International

InBios International is a privately held, established leader in the infectious disease diagnostics market, with over 25 years of experience. The company leverages its expertise in immunodiagnostics to develop and manufacture a broad portfolio of tests, ranging from rapid point-of-care assays to ELISA kits, for both endemic and emerging pathogens. It has demonstrated agility in responding to public health crises, securing FDA EUAs for COVID-19 tests and government contracts for biothreat agents. With a state-of-the-art manufacturing facility in Seattle and strong regulatory credentials, InBios is positioned to address significant global diagnostic needs.

Proprietary immunodiagnostic platforms for Enzyme-Linked Immunosorbent Assay (ELISA) and Lateral Flow Assay (LFA) formats, with in-house development and production of key antigens and antibodies.

InBios competes in a crowded infectious disease diagnostics market against giants like Abbott, Roche, and QuidelOrtho, particularly in respiratory testing. Its differentiation lies in its deep focus on neglected tropical diseases, biothreat agents, and its agility in responding to emerging outbreaks with rapid assay development.